Unfortunately, known driver mutations in HCC, namely TERT, TP53, CTNNB1, are not targetable by drugs and HCC is well-known for its resistance to systemic therapy [6, 7]. The gene discussed is CTNNB1; the disease is hepatocellular carcinoma.